← Leaderboards
Maurizio Zanetti
University Of California San Diego
$7,640,160
Attributed
$8,958,593
Total exposure
11
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$7,862,426 · 10
FDA$1,096,167 · 1
By mechanism
R01$7,340,556 · 6
R21$1,231,787 · 3
R56$386,250 · 1
M01$0 · 1
Top collaborators
- Hannah Kathryn Carter5 shared
- Santosh Kesari3 shared
Most similar at University Of California San Diego
Same institution · by research overlap
- Robert C Rickert$18,269,835
- John P. Huelsenbeck$2,246,712
Others in their field
Top investigators on “Laboratory Mouse”
- Richard K. Wilson · Washington University$122,948,010
- Frank Patrick McCormick · University Of California San Francisco$87,382,096
- David Heimbrook · Leidos Biomedical Research, Inc.$81,904,667
- Kc Kent Lloyd · University Of California At Davis$56,148,943
- Alfred G Gilman · University Of Texas Sw Med Ctr/Dallas$53,869,943
- Carol J Bult · Jackson Laboratory$47,860,052
Research focus
Laboratory MouseCytotoxic T LymphocyteVaccine DevelopmentDendritic CellsCellsIn VivoDesignBaseNeoplasm /Cancer VaccineTumor AntigensMalignant NeoplasmsImmunityMediatingB LymphocyteT-LymphocyteB-LymphocytesTumorCancer CellGenetically Modified AnimalsLinkResponseIn VitroImmuneRegulation
Grant awards (41)
(PQ3) Disruption of immune surveillance by aneuploidy and aberrant MHCII expression$310,000
R01 · FY2021 · CA · contact PI
(PQ3) Disruption of immune surveillance by aneuploidy and aberrant MHCII expression$310,000
R01 · FY2020 · CA · contact PI
(PQ3) Disruption of immune surveillance by aneuploidy and aberrant MHCII expression$300,700
R01 · FY2019 · CA · contact PI
(PQ3) Disruption of immune surveillance by aneuploidy and aberrant MHCII expression$310,000
R01 · FY2018 · CA · contact PI
(PQ3) Disruption of immune surveillance by aneuploidy and aberrant MHCII expression$310,000
R01 · FY2017 · CA · contact PI
Phase 2 Study of Vascular-Targeted Prodrug (G-202) for the Treatment of Recurrent Glioblastoma$296,167
R01 · FY2017 · FD
Phase 2 Study of Vascular-Targeted Prodrug (G-202) for the Treatment of Recurrent Glioblastoma$400,000
R01 · FY2016 · FD
Phase 2 Study of Vascular-Targeted Prodrug (G-202) for the Treatment of Recurrent Glioblastoma$400,000
R01 · FY2015 · FD
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes$168,563
R21 · FY2015 · CA · contact PI
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes$202,275
R21 · FY2014 · CA · contact PI
Genetically-Programmed APC Vaccines Against Viruses$386,250
R56 · FY2011 · AI · contact PI
Strategies of Vaccination Against MUC.1 Antigen$243,546
R01 · FY2008 · CA · contact PI
Genetically-Programmed APC Vaccines Against Viruses$292,988
R01 · FY2007 · AI · contact PI
Strategies of Vaccination Against MUC.1 Antigen$243,546
R01 · FY2007 · CA · contact PI
Genetically-Programmed APC Vaccines Against Viruses$301,332
R01 · FY2006 · AI · contact PI
Strategies of Vaccination Against MUC.1 Antigen$250,347
R01 · FY2006 · CA · contact PI
Genetically-Programmed APC Vaccines Against Viruses$307,583
R01 · FY2005 · AI
Novel APC Vaccine to Induce Anti-Tumor T cell Immunity$304,380
R01 · FY2005 · CA
Strategies of Vaccination Against MUC.1 Antigen$255,540
R01 · FY2005 · CA
Conformationally-Constrained PA Anthrax Vaccine$196,041
R21 · FY2005 · AI
Novel APC Vaccine to Induce Anti-Tumor T cell Immunity$304,380
R01 · FY2004 · CA
Conformationally-Constrained PA Anthrax Vaccine$209,033
R21 · FY2004 · AI
Novel APC Vaccine to Induce Anti-Tumor T cell Immunity$304,380
R01 · FY2003 · CA
TARGETED THERAPEUTIC VACCINATION IN PROSTATE CANCER$273,600
R01 · FY2003 · CA
Novel APC Vaccine to Induce Anti-Tumor T cell Immunity$304,380
R01 · FY2002 · CA
TARGETED THERAPEUTIC VACCINATION IN PROSTATE CANCER$273,600
R01 · FY2002 · CA
Transgenic B-Cell Immunogenes$228,000
R21 · FY2002 · AI
CTL AGAINST CELLULAR ENZYME TELOMERASE IN CANCER$0
M01 · FY2002 · RR
CTL AGAINST CELLULAR ENZYME TELOMERASE IN CANCER$0
M01 · FY2002 · RR
CTL AGAINST CELLULAR ENZYME TELOMERASE IN CANCER$0
M01 · FY2002 · RR
CTL AGAINST CELLULAR ENZYME TELOMERASE IN CANCER$0
M01 · FY2002 · RR
TARGETED THERAPEUTIC VACCINATION IN PROSTATE CANCER$273,600
R01 · FY2001 · CA
STRATEGIES OF VACCINATION AGAINST MUC-1 ANTIGEN$252,980
R01 · FY2001 · CA
Transgenic B-Cell Immunogenes$227,875
R21 · FY2001 · AI
CTL AGAINST CELLULAR ENZYME TELOMERASE IN CANCER$0
M01 · FY2001 · RR
CTL AGAINST CELLULAR ENZYME TELOMERASE IN CANCER$0
M01 · FY2001 · RR
TARGETED THERAPEUTIC VACCINATION IN PROSTATE CANCER$272,700
R01 · FY2000 · CA
STRATEGIES OF VACCINATION AGAINST MUC-1 ANTIGEN$244,807
R01 · FY2000 · CA
CTL AGAINST CELLULAR ENZYME TELOMERASE IN CANCER$0
M01 · FY2000 · RR
CTL AGAINST CELLULAR ENZYME TELOMERASE IN CANCER$0
M01 · FY2000 · RR
CTL AGAINST CELLULAR ENZYME TELOMERASE IN CANCER$0
M01 · FY2000 · RR